Compliance Certificate under reg. 74 (5) of SEBI (DP) Regulations, 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd has submitted a compliance certificate under SEBI Regulation 74(5) to BSE for the quarter ended 30 September 2025. The certificate was issued by the company's Registrar and Share Transfer Agent, Skyline Financial Services Pvt Ltd, on 3 October 2025 and signed by Managing Director Nanjappan Aravind on 13 October 2025. It confirms that physical share certificates received for dematerialisation were duly verified, mutilated, cancelled, and the depository's name substituted as the registered owner within 15 days. This is a standard quarterly procedural requirement and not related to any corporate action, fundraising, or business change.
No impact on shareholders or stock price. This is a routine quarterly compliance filing confirming proper handling of share dematerialisation requests; it carries no financial or strategic information.